1 月 2 日，阿斯利康和默沙东联合宣布其 PARP 抑制剂利普卓（英文商品名：Lynparza，通用名：奥拉帕利）在国内获批新适应症，用于接受过新辅助或辅助化疗的携带有害或疑似有害胚系 BRCA 突变（gBRCAm）、人表皮生长因子受体 ...

A Comprehensive Review of Epidemiology, Risk Factors, and Treatment Strategies. Advances in Breast Cancer Research, 14, 1-15. doi: 10.4236/abcr.2025.141001 . Noncommunicable diseases like various ...

2025年1月2日——阿斯利康与默沙东联合宣布其PARP抑制剂利普卓®（英文商品名：Lynparza，通用名：奥拉帕利）在华获批用于接受过新辅助或辅助化疗的携带有害或疑似有害胚系BRCA突变（gBRCAm）、人表皮生长因子受体2（HER2）阴性早期高 ...

Learn how genetic testing impacts life insurance applications, from potential denials to higher rates, and discover tips to ...

The Australian government announces Olaparib now available on the PBS for HER2-negative metastatic breast cancer patients with mutated BRCA1 or BRCA2 gene.

Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

Men of African ancestry were also found to be at higher risk of developing a more aggressive form of prostate cancer.

For the first time in Nepal, genetic testing, also known as "Gene Sequencing," related to breast cancer (BRCA1 and BRCA2) has ...

A breakthrough study has identified the genetic risk factors that contribute to increased prostate cancer in African men. The ...

Prostate cancer is one of the most common cancers in men worldwide, primarily affecting older men. The prostate is a small, walnut-shaped gland located just below the bladder and in front of the ...

OlympiA 是一项前瞻性多国多中心双盲临床研究，旨在探究 HER2-、携带 gBRCA 突变且具有高复发风险的早期乳腺癌患者的治疗效果。入组患者在完成（新）辅助治疗及局部治疗后，按 1:1 比例随机分配接受为期 1 ...